OrbiMed’s Xoma XOMA Stock Holding History

OrbiMed’s Portfolio XOMA Stock Details XOMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-100,000	Closed	-$7.18M	–	144
2014 Q4	$7.18M	Sell	100,000 -21,850	-18%	-$1.87M	0.07%	104
2014 Q3	$10.3M	Hold	121,850	–	–	0.11%	96
2014 Q2	$11.2M	Hold	121,850	–	–	0.13%	80
2014 Q1	$12.7M	Sell	121,850 -19,631	-14%	-$2.85M	0.16%	79
2013 Q4	$19M	Buy	141,481 +2,127	+2%	+$214K	0.28%	64
2013 Q3	$12.5M	Buy	139,354 +10,058	+8%	+$914K	0.22%	67
2013 Q2	$9.39M	Buy	+129,296	New	+$9.62M	0.2%	79

Other funds holding XOMA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OrbiMed's XOMA Position: Q1 2015 in Review

OrbiMed sold out of Xoma (XOMA) in Q1 2015, closing a stake of 100,000 shares — an estimated $7.18M sold.

OrbiMed first reported a position in XOMA in Q2 2013 and held it in 7 quarters. The position peaked at $19M in Q4 2013. 98 funds tracked by Wall St. Rank hold XOMA as of Q1 2015.

OrbiMed reported no remaining Xoma position as of Q1 2015 after selling out during the quarter.
OrbiMed sold 100,000 Xoma shares in Q1 2015, an estimated $7.18M.
OrbiMed first reported a position in Xoma in Q2 2013 and held it in 7 quarters.
OrbiMed's Xoma position peaked at $19M in Q4 2013.
98 funds tracked by Wall St. Rank held Xoma as of Q1 2015.

Based on OrbiMed's 13F filing for Q1 2015, filed 15 May 2015.